Lorena 1997.

Methods	1‐month dietary run‐in period 2‐month before and after trial
Participants	20 men and women with type IIa and IIb hypercholesterolaemia age 40‐50 years exclusion criteria:diabetes mellitus, impaired hepatic and renal function, secondary hypercholesterolaemia, drug or alcohol abuse concomitant treatment with anticoagulants and antiplatelet drugs macrovascular complications history Fluvastatin 40 mg/day baseline TC : 7.2 mmol/L (278 mg/dL) Fluvastatin 40 mg/day baseline LDL‐C : 5.1 mmol/L (197 mg/dL) Fluvastatin 40 mg/day baseline HDL‐C : 1.3 mmol/L (50 mg/dL) Fluvastatin 40 mg/day baseline triglycerides: 2.3 mmol/L (204 mg/dL)
Interventions	Fluvastatin 40 mg/day for 8 weeks
Outcomes	per cent change from baseline at 8 weeks of plasma TC, LDL‐C, HDL‐C, and triglycerides
Source of Funding	unknown
Notes	SDs were imputed by the method of Furukawa 2006
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Controlled before and after design
Allocation concealment (selection bias)	High risk	Controlled before and after design
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Lipid parameter measurements unlikely influenced by lack of blinding
Blinding of outcome assessment (detection bias) LDL‐cholesterol	Low risk	Lipid parameters were measured in a remote laboratory
Blinding of outcome assessment (detection bias) WDAEs	High risk	No comparison possible
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants were included in the efficacy analysis
Selective reporting (reporting bias)	Low risk	LDL‐C outcome was reported
Other bias	Unclear risk	Source of funding was not reported